EP2145187B1 - Pas-färbung mit nachweis im infrarotbereich - Google Patents

Pas-färbung mit nachweis im infrarotbereich Download PDF

Info

Publication number
EP2145187B1
EP2145187B1 EP08745665A EP08745665A EP2145187B1 EP 2145187 B1 EP2145187 B1 EP 2145187B1 EP 08745665 A EP08745665 A EP 08745665A EP 08745665 A EP08745665 A EP 08745665A EP 2145187 B1 EP2145187 B1 EP 2145187B1
Authority
EP
European Patent Office
Prior art keywords
glycogen
disease
biological sample
detecting
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP08745665A
Other languages
English (en)
French (fr)
Other versions
EP2145187A4 (de
EP2145187A1 (de
Inventor
Elfrida Benjamin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amicus Therapeutics Inc
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of EP2145187A1 publication Critical patent/EP2145187A1/de
Publication of EP2145187A4 publication Critical patent/EP2145187A4/de
Application granted granted Critical
Publication of EP2145187B1 publication Critical patent/EP2145187B1/de
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/48—Reserve carbohydrates, e.g. glycogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Definitions

  • the present invention relates to a novel method for quantifying glycogen and other polysaccharides in biological samples using a fluorescent Periodic acid-Schiff (PAS) reaction with detection in the infrared range.
  • PAS Periodic acid-Schiff
  • Polysaccharides are complex carbohydrates comprised of polymers made up of many monosaccharides joined together by glycosidic linkages.
  • Polysaccharides include storage polysaccharides such as starches and glycogen, and structural polysaccharides such as cellulose, acid polysaccharides containing sialic acid or sulfuric ester groups, and chitin.
  • Polysaccharides have diverse biological functions including long term storage of sugars (for energy), and structural support and protection to organisms; cellulose is a major component of cell walls in plants and bacteria, and chitin is a component of fungi cell walls and exoskeletons of arthropods.
  • Polysaccharides are also involved in molecular recognition (antigens) by cells of the immune systerm.
  • Glycogen is a storage polysaccharide comprised of glucose. Most of the glucose units are linked by ⁇ -1,4 glycosidic bonds, but approximately 1 in 12 glucose residues also makes ⁇ -1,6 glycosidic bond with a second glucose, which results in the creation of a branch. Glycogen is present in a wide variety of tissues, including skin, liver, parathyroid glands and skeletal and cardiac muscle. Detection of glycogen is used in clinical settings for the diagnosis of diseases including cancer, infections (fungus, Chlamydia ), diabetes (Type 1), myopathies, glycogen storage disease (Pompe disease), and other glycogenoses.
  • diseases including cancer, infections (fungus, Chlamydia ), diabetes (Type 1), myopathies, glycogen storage disease (Pompe disease), and other glycogenoses.
  • Histochemical detection of glycogen also is used to identify structures such as connective tissues, mucus, and basal laminae, corporal amylacea, polygucosan bodies and other substances in biological samples, all of which contain a high proportion of carbohydrate macromolecules (glycogen, glycoprotein, proteoglycans).
  • PAS is used to stain neutral mucopolysaccharides, such as those in glands of the GI tract and in prostate; simple acidic polysaccharides containing sialic acid, such as those found in epithelial cells; and complex sulfated acid polysaccharides such as those found in adenocarcinomas.
  • PAS Periodic acid-Schiff
  • a method for staining of blood cells with periodic acid/salicyloyl hydrazine has been described ( Burns et al., Blood. 1966; 28:674-682 ).
  • the method is that of Stoward in which acidified solutions of salicyloyl hydrazide is conjugated with dialdehydes formed from the periodic acid oxidation of vicinal glycols in glycogen. The reactive sites were said to fluoresce an intense blue on exposure to ultraviolet light.
  • Fluorescence intensity measurement is another approach used commonly to quantify relative or absolute amounts of select biological materials. Fluorescence occurs where a molecule in an excited state (i.e. , excited by absorption of EM radiation) emits light as it falls back to the lower energy state. The emission typically is at a longer wavelength than the wavelength of the excitatory radiation absorbed, and is in the visible range of the electromagnetic spectrum. Quantitation of fluorescence intensity is straightforward, can be readily achieved with instruments ranging from microtiter plate readers, fluorescence scanners, fluorescence and confocal microscopes. The microtiter plate reader or fluorescence scanner format is particularly suitable for simultaneous quantification and comparison of a large number of samples, such as is necessary in high-throughput applications.
  • Near-infrared fluorescence is a technique useful for in vivo imaging, e.g. , for detecting tumors. This method is based on the fact that living tissue transmits fluorescence with wavelengths in the near-IR (about 700 nm) more efficiently than it transmits light with wavelengths in the visible range, due to increased photon penetration. Both organic and inorganic fluorescence contrast agents are now available for chemical conjugation to targeting molecules for imaging. However, this technique is for in vivo detection and imaging and has not been employed to quantitate material ex vivo in biological samples.
  • fluorescence imaging microscopy One strategy used to overcome the limitations of the visible range fluorescence measurements is fluorescence imaging microscopy ( Brenner et al., J Histochem Cytochem. 1976. 24:100-11 ). This method requires the assembly and integration of sophisticated equipment including a light source and appropriate filters for excitation, a microscope with sensitive optics, fine focus, an XY stage control for spatially-resolved sample imaging, emission filters, a sensitive camera for image capture, and a computer for microscope control, equipped with image collection and processing software for documentation. Focusing, XY positioning, filter configuration, image capture and collection are carried out independently for each sample and fluorophore.
  • Image processing software is used to merge the two images from each fluorophore of a given sample to view the spatial localization of the two fluorophores simultaneously. This final merged image is a qualitative image of the spatial distribution of the fluorophore probes. Additional image quantification software, that is designed to select a region of interest and quantify fluorescence intensity within that region for each fluorophore is used to quantify the fluorescence. Thus, fluorescence is measured within areas of cells or tissues of interest, and in a region defined as background. Each fluorescence measurement is corrected for the size of the region, and then background subtracted. Theffy and focal resolution that is achieved with this methodology allows for sufficient signal to background detection in the visible range.
  • the present invention provides a method for detecting polysaccharides in a biological sample using Periodic Acid-Schiff staining followed by quantitative detection in the IR range.
  • detection is at a wavelength in a range from about 700 nM to 800 nM. In a specific embodiment, the detection is at a wavelength of about 800 nM.
  • the polysaccharide is glycogen
  • the biological sample is derived from a human or animal.
  • the biological sample is derived from a human subject having or suspected of having a glycogen storage disease including but not limited to Pompe disease (including infantile-onset Pompe disease); Cori's-Forbes' disease; Andersen's disease; Tauri's disease; McArdle's disease; Phosphorylase b Kinase deficiency (Glycogenosis type VIII); equine Glycogen Branching Deficiency; Phosphoglycerate kinase A-isoform deficiency (Glycogenosis IX); Phosphoglycerate M-mutase deficiency (Glycogenosis type X); triosephosphate isomerase (TIM) deficiency; pulmonary interstitial glycogenosis; diabetic nephropathy; and Lafora's disease (myoclonus epilepsy).
  • Pompe disease including infantile-onset Pompe disease
  • Cori's-Forbes' disease Andersen's disease
  • the biological sample isolated is cells or tissue.
  • the tissue is selected from the group consisting of skin, liver, kidney, heart, brain, or skeletal muscle.
  • the present invention further relates to quantitating the level of polysaccharides present in the biological sample by comparing the amount of emitted light with that emitted from standards of known quantities of polysaccharides.
  • the present invention also provides a method monitoring the efficacy of treatment in a subject being treated for a glycogen storage disease by
  • IR fluorescence is readily quantifiable, exhibits superior signal-to-noise, superior fluorescence penetration into thick sections of tissue, and suitability for high-throughput applications.
  • IR fluorescence detection and glycogen quantification using PAS is superior to currently available methods for quantitating glycogen content from stained cells or tissues.
  • IR spectroscopy is the measurement of the wavelength and intensity of the absorption of mid-infrared light by a chemical sample. IR absorption spectroscopy is based on the ability of molecules to absorb IR radiation. This absorption of energy (photons) causes the molecules go into a higher energy state, where they vibrate or rotate.
  • the vibrations or rotations within a molecule cause a net change in the dipole moment of the molecule, which change can be measured using infrared spectrometers.
  • the frequencies at which there are absorptions of IR radiation (“peaks” or “signals”) can be correlated directly to bonds within the compound being analyzed. Each molecule will have a unique IR spectrum.
  • the present invention relates to the detection and/or quantitative measurement of glycogen levels in biological samples using IR fluorescence.
  • Autofluorescence of biological materials is significantly lower in the infrared range ( Frangioni JV., Curr Opin Chem Biol. 2003; 7:626-634 ; Ohnishi et al., Am J Transplant. 2006; 6:2321-31 ).
  • fluorescence is the emission of light at a longer wavelength than the wavelength of the excitatory energy absorbed.
  • the difference in wavelength between the peak absorbance and peak emission is the Stokes Shift.
  • This method differs from IR absorbance spectroscopy, above, which requires that the frequency of infrared radiation passing through a molecular substance be equal to, or in resonance with, a frequency of two bonded atoms vibrating.
  • absorbance spectroscopy the amount of transmitted light is measured at the same wavelength as the absorbed radiation, and the amount of transmitted light is inversely proportional to the amount of light absorbed.
  • the present invention demonstrates that fluorescent light detected in the IR range is superior to detection in the visible range for quantitating polysaccharide content of biological samples. This is in contrast to many fluorescent imaging systems, which contain filters for preventing the transmission of infrared light because only the visible light is desired.
  • infrared covers the range of electromagnetic (EM) radiation with wavelengths of between about 700 nm-1 mm). This is in contrast to the visible red range which emits in the 600-640 nm range.
  • the IR wavelength used to detect fluorescence is between about 700 nm and 800 nm. In another embodiment, the wavelength is about 800 nm.
  • Fluorescence is the phenomenon in which light energy (“exciting light”) is absorbed by a molecule resulting in the molecule becoming “excited.” After a pre-described interval, the absorbed light energy is emitted by the excited molecule. The wavelength of the emitted light is typically at a longer wavelength than the exciting light. This emitted light is referred to as fluorescent light. A molecule that exhibits fluorescence is referred to as a "fluorophore.” The relationship between wavelengths of light and degree of excitation of a given fluorophore at that wavelength is described by the "excitation spectrum" of the fluorophore. The excitation spectrum is also called the excitation wavelength range.
  • the relationship between the wavelength of light and the intensity of the fluorescence emission at that wavelength is described by the emission spectrum or fluorescence spectrum of the fluorophore.
  • the emission spectrum is also called the emitted wavelength range.
  • the excitation maximum is the wavelength of exciting light at which fluorescence of the fluorophore reaches maximum intensity.
  • the emission maximum is the wavelength of light emitted by the excited fluorophore when its fluorescence is at maximum intensity.
  • glycogenosis or "glycogenoses” or “glycogen storage disease” refers to diseases or pathologies characterized by abnormal accumulation of glycogen in tissues. Such diseases or pathologies include but are not limited to the following: Pompe disease (acid maltase deficiency; Glycogenosis type II); Debrancher deficiency (Cori's-Forbes' disease; Glycogenosis type III); Branching deficiency (Glycogenosis type IV; Andersen's disease); Phosphofructokinase deficiency-M isoform (Tauri's disease; Glycogenosis type VII); Phosphorylase b Kinase deficiency (Glycogenosis type VIII); Phosphoglycerate kinase A-isoform deficiency (Glycogenosis IX); Phosphoglycerate M-mutase de
  • TIM triosephosphate isomerase
  • biological sample refers to cells or tissue isolated from a human, animal, or insect, including post-mortem, which is used in an assay for diagnostic, prognostic, or histological procedures.
  • biological samples can be from any cell or tissue from a human, animal, or insect, but especially derived from the kidney, liver, brain, and skeletal muscle.
  • the biological sample is a tissue comprising of several cell types.
  • subject refers to any living eukaryotic organism including humans, animals, and insects, from which a biological sample can be obtained.
  • the subject is a mammal, particularly a human, horse, or mouse.
  • the subject is a non-mammalian animal such as a quail.
  • the term "effective treatment” refers to a treatment administered to a subject in need of such treatment which results in an improvement in, amelioration, or prevention of, one or more clinical symptoms, or improvement or reversal of one or more surrogate clinical markers that may be indicators of disease pathology.
  • the subject has infantile-onset Pompe disease and the surrogate clinical marker is glycogen accumulation in tissues, where a reduction in glycogen accumulation indicates that the treatment is effective.
  • the terms “about” and “approximately” shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Typical, exemplary degrees of error are within 20 percent (%), preferably within 10%, and more preferably within 5% of a given value or range of values. Alternatively, and particularly in biological systems, the terms “about” and “approximately” may mean values that are within an order of magnitude, preferably within 5-fold and more preferably within 2-fold of a given value. Numerical quantities given herein are approximate unless stated otherwise, meaning that the term “about” or “approximately” can be inferred when not expressly stated.
  • purified refers to material, such as a cell, that has been isolated under conditions that reduce or eliminate unrelated materials, i.e., contaminants.
  • a purified cell is preferably substantially free of other cell types with which it is associated in a tissue.
  • substantially free is used operationally, in the context of analytical testing of the material.
  • purified material substantially free of contaminants is at least 50% pure; more preferably, at least 90% pure, and more preferably still at least 99% pure. Purity can be evaluated by conventional means, e.g., chromatography, gel electrophoresis, immunoassay, composition analysis, biological assay, and other methods known in the art.
  • Pompe disease (acid maltase deficiency) is caused by a deficiency in the enzyme acid ⁇ -glucosidase (GAA). GAA metabolizes glycogen, a storage form of sugar used for energy, into glucose. The accumulation of glycogen leads to progressive muscle myopathy throughout the body which affects various body tissues, particularly the heart, skeletal muscles, liver, and nervous system. According to the National Institute of Neurological Disorders and Stroke, Pompe disease is estimated to occur in about 1 in 40,000 births.
  • GAA acid ⁇ -glucosidase
  • Juvenile onset Pompe disease first presents in early to late childhood and includes progressive weakness of the respiratory muscles in the trunk, diaphragm, and lower limbs, as well as exercise intolerance. Most juvenile onset Pompe patients do not live beyond the second or third decade of life. Adult onset symptoms involve generalized muscle weakness and wasting of respiratory muscles in the trunk, lower limbs, and diaphragm. Some adult patients are devoid of major symptoms or motor limitations.
  • Pompe disease Unless infantile or identified during pre-natal screening, diagnosis of Pompe disease is a challenge. Diagnosis of adult-onset Pompe is even more difficult since number, severity, and type of symptoms a patient experiences vary widely, and may suggest more common disorders such as muscular dystrophies. Diagnosis is confirmed by measuring ⁇ -glucosidase activity and/or detecting pathologic levels of glycogen from biological samples. Currently the only approved therapy is enzyme replacement therapy with recombinant ⁇ -glucosidase.
  • Pompe disease is one of several of glycogen pathologies. Others include Debrancher deficiency (Cori's-Forbes' disease; Glycogenosis type III); Branching deficiency (Glycogenosis type IV; Andersen's disease); Myophsophorylase (McArdle's disease, Glycogen storage disease V); Phosphofructokinase deficiency-M isoform (Tauri's disease; Glycogenosis type VII); Phosphorylase b Kinase deficiency (Glycogenosis type VIII); Phosphoglycerate kinase A-isoform deficiency (Glycogenosis IX); Phosphoglycerate M-mutase deficiency (Glycogenosis type X).
  • Debrancher deficiency Cori's-Forbes' disease; Glycogenosis type III
  • Diabetes mellitus Poorly controlled diabetes mellitus results in glycogenic hepatopathy (accumulation in liver parenchymal cells) and nephropathy (glomeruli) due to the accumulation of glycogen.
  • Polysaccharide storage myopathy is a neuromuscular condition found in sufferers of Glycogen Branching Enzyme Deficiency (Glycogen Storage Disease IV; Equine Rhabdomyolysis Syndrome), including American Quarter horses and related breeds. In affected horses, up to 40% of the type II muscle fibers have been found to have an acid mucopolysaccharide inclusion comprised mostly of glycogen. This results in exercise intolerance, particularly at high speeds. The abnormal accumulation typically is due to a mutation in the glycogen branching enzyme 1 (GBE1). Surgical or needle muscle biopsies which are stained by PAS or stained to detect increased ubiquitin provide a definitive diagnosis ( Valentine et al., Vet Pathol. 2006; 43:270-275 ).
  • Parasite infections Many parasites, especially fungi, store food as glycogen and can thus be diagnosed using the method of the present invention.
  • filamentous fungi skin, nails and scalp and they constitute around 30 out of about 55 species of fungus considered to be pathogenic for man.
  • Tinea capitis Tinea corporis, Tinea barbae, Tinea pedis (Athlete's foot), Tinea unguium, Blastomyces dermitiditis, Histoplasma capsulatum, and Cryptococcus neoformans, Sporothrix schenckii, the yeast form of Paracoccidioides brasiliensis, and onychomycosis (nail fungus).
  • Other parasites which produce glycogen are bacteria and parasitic protozoa, and include Toxoplasma gondii ( Guimaraes et al., Mem Inst Oswaldo Cruz. 2003 Oct;98(7):915-7 ); Tropheryma whipplei (Whipple's disease; Deriban et al., Curr Med Chem. 2006;13(24):2921-6 ); Entamoeba histolytica and parasitic helminthes such as Digenean flukes, the tapeworms (Cestodes) and the roundworms (Nematodes). Whipple's disease especially is caused by a cultivation-resistant bacteria and diagnosis thus must be made by histologic analysis.
  • Elevated levels of glycogen or mucinous polysaccharides are characteristic of cancers such as chondroid lipoma, colorectal cancer and other carcinomas (e.g., brain, breast, lung, kidney). In colorectal carcinomas, it was shown using PAS staining that some of the malignant cells always produce PAS-positive mucin ( Lushbaugh et al., Digestive Diseases and Sciences. 1985; 30: 119S-125S ; U.S. patent 6,187,591 ). In another study, glycogen levels were shown to be highest in colorectal tumors with a high proportion of cells in G1, and decreased with progression to S phase. Takahashi et al., J. Gastroenterology.
  • Glycogen-rich clear cell carcinoma of the breast also is characterized as a carcinoma in which more than 90% of the neoplastic cells have abundant clear cytoplasm that contains PAS-positive diastase-labile material, consistent with glycogen.
  • chondroid lipomas are characterized by the presence of cells resembling chondroblasts and lipoblasts, mature adipose tissue, and myxoid matrix. They have irregular nuclei surrounded by clear and vacuolated cytoplasm. The vacuoles can be shown to contain lipid using the oil red 0 stain, and glycogen using PAS stain.
  • Glycogen also is found in tumors such as pancreatic islet cell tumors ( Ladriere et al., Diabetes research. 2003; 37: 9-14 ; adenosquamous carcinomas of the cervix ( Fujiwara et al., Cancer. 1995; 76:1591-1600 ); and in anaplastic astrocytoma, glioblastoma multiforme ( Kotonski et al., Acta Biochim Pol. 2001;48(4):1085-90 ).
  • Barrett's esophagus is a condition in which the esophagus, the muscular tube that carries food and saliva from the mouth to the stomach, changes so that some of its lining is replaced by a type of tissue similar to that normally found in the intestine.
  • the risk of developing esophageal adenocarcinoma is 30 to 125 times higher in people who have Barrett's esophagus than in people who do not. Diminished or absent glycogen content is indicative of Barrett's esophagus or early esophageal squamous cell carcinoma.
  • Glycogenic acanthosis is another esophageal condition affecting elderly people.
  • cytoplasmic glycogen accumulates in the squamous epithelial cell lining of the esophagus, which causes focal plaque-like thickening of the mucosa.
  • Glycogenic acanthosis may manifest on double-contrast studies as multiple small nodules or plaques.
  • Lafora's disease also known as Lafora's disease, this type of epilepsy is characterized by neuronal polyglucosan inclusions, resulting in myoclonic seizures and/or hallucinations.
  • Polyglucosan intracellular inclusion bodies called Lafora bodies, resemble glycogen with reduced branching, suggesting an alteration in glycogen metabolism ( Fernandez-Sanchez et al., Human Molecular Genetics. 2003; 12: 3161-3171 ).
  • the laforin protein is a phosphatase which contains a carbohydrate binding domain. Laforin interacts with another phosphatase, R5, its substrate, glycogen synthase, and intracellular glycogen to form a multiprotein complex associated with intracellular glycogen particles.
  • Lutenizing hormone and follicle-stimulating hormone are glycopeptide hormones; cells containing these hormones stored in their secretory vacuoles stain positive with PAS.
  • Hepatic glycogen stores have long been known to decrease with starvation, trauma, acute stress, and shock, and can be evaluated using post-mortem liver biopsies. Thogmartin et al., Am J Forensic Med Pathol. 2001;22(3):313-8 .
  • alcoholic polyneuropathy is characterized by degenerating giant neurons in sympathetic ganglia which, upon autopsy, were shown to be filled with eosinophilic, periodic acid-Schiff reaction positive material.
  • PAS has been used to detect bacterial contamination in food such as milk ( Moats, J Bacteriol. 1959; 78(4): 589-593 ) and poultry; in cosmetics such as lotions ( Bernd et al., Annals of Internal Medicine. 1996; 125; 799-806 ); in contact lens solutions with e.g. , Acanthamoeba keratitis ( Awwad et al., Eye & Contact Lens: Science & Clinical Practice. 2007. 33(1):1-8 ); and in water contamination with microorganisms (including ground water, drinking water, river and lake water).
  • cells e.g. , fibroblasts
  • coverslips or microtiter plates may be tissue culture treated, or coated with fibronectin or another similar adhesion molecule.
  • cells are fixed in 3.7% formaldehyde in PBS for 0.5 h at room temperature, then washed with deionized water for approximately 1 minute. PAS staining is then performed. Briefly, the cells are treated for about 5 minutes with 1% periodic acid, followed by washing for 1 minute in tap water, followed by a rinse in purified, deionized (e.g. , milli-Q-water) water.
  • Schiff's reagent is then applied (1% pararosaniline, 4% sodium metabisulfite, and .25 mol/l hydrochloric acid) and the sections incubated for about 15 minutes at room temperature. Following is another wash in milli-Q water, followed by rinsing for about 10 minutes with tap water. When using cells in a microtiter plate, the plate should be dried overnight prior to analysis. As a negative control, cells are pre-treated with diastase, which breaks down glycogen and makes it undetectable using PAS.
  • tissue sections entails harvest of a fresh piece of organ tissue (e.g. liver, heart, etc.) The tissue is then fixed in 3.7% formaldehyde in 90% ethanol at room temperature overnight. The tissue is then embedded in paraffin, sectioned at 5 ⁇ m thickness, then mounted onto a glass slide. Sections are deparaffinized in xylene, and re-hydrated in a graded ethanol series into a final solution of 100% water. For diastase treatment, the sections are incubated with 0.5% diastase in deionized water at room temperature for 20 minutes. The slides are then washed in deionized water. Afterward, PAS staining is then performed. Slides are immersed in 1% periodic acid for 5 min at room temperature.
  • organ tissue e.g. liver, heart, etc.
  • Slides are then rinsed several times in deionized water. Afterward, slides are immersed in Schiff's reagent for 15 min at room temperature. Slides are washed in running tap water for 5 minutes, the dried at room temperature or dehydrated through a graded ethanol series. A coverslip is then applied to the slide with xylene-based mounting media.
  • Fluorescence can be measured on a laser-based IR scanner, such as Odyssey®, manufactured by LiCor, Inc.
  • This approach can be extended to quantify absolute amounts of glycogen in cells and tissues by combining PAS staining of varying concentrations of an external glycogen standard, and quantifying the IR fluorescence emitted from the standard concentrations.
  • a linear or non-linear regression analysis can be performed on the standard curve data, and the theoretical line or curve can be used to calculate absolute glycogen values from samples stained with PAS and measured using IR detection.
  • the present invention also provides for a method to develop commercial diagnostic/prognostic test kits in order to make therapeutic treatment decisions.
  • the kit provides all materials discussed above and exemplified below for preparing and running the assay in one convenient package, including instructions and an analytic guide.
  • kits will include microtiter plates, superfibronectin, diastase, periodic acid solution, Schiff's reagent, deionized water (purified), known glycogen standards, and instructions for IR detection.
  • PAS staining and detection in the IR using an infrared scanner at a wavelength of 800 nm was applied to cells from patients with glycogen storage disease type II (Pompe disease).
  • PM-11 Pompe fibroblasts were obtained from Dr. W.J. Kleijer, Department of Cell Biology & Genetics, Erasmus University, The Netherlands. PM-12 Pompe fibroblasts were purchased from Coriell (catalog # GM03329). CRL-2076 fibroblasts (negative control) were purchased from American Type Culture Collection (Manassas, VA). All fibroblast lines were routinely cultured at 37°C, 5% CO 2 , in growth medium consisting of Dulbecco's Modified Minimum Essential Medium containing 15% fetal bovine serum (Hyclone, Logan, UT), 100 U/mL penicillin; 100 ⁇ g/mL streptomycin, and 2 mM L-glutamine.
  • Dulbecco's Modified Minimum Essential Medium containing 15% fetal bovine serum (Hyclone, Logan, UT), 100 U/mL penicillin; 100 ⁇ g/mL streptomycin, and 2 mM L-glutamine.
  • borosilicate coverslip glass bottom 96-well black plates (Nunc; catalog # 164588) are coated with superfibronectin (Sigma). Borosilicate coverslip glass bottom plates were found to have a better signal-to-background ratio (4-fold greater) than either tissue culture-treated plastic or optical-quality polymer plates (data not shown). Briefly, 100 ⁇ L of 5 ⁇ g/mL superfibronectin (Sigma) is pipetted into each well and the plate is incubated at 37°C for 2 hours. The fibronectin solution is aspirated, the plate is washed 2 times with sterile PBS, and allowed to dry in an open-air sterile environment overnight. Plates can be stored for up to two weeks at 4°C (wrapped in parafilm).
  • IR Detection Following the overnight incubation, the plate is read on a laser-based Odyssey IR scanner (Li-Cor, Inc.) at emission wavelengths of 700 nm (near-IR) or 800 nm (IR). The detector counts IR and near-IR fluorescence emissions independently or simultaneously from the samples, and reports these counts as arbitrary units. The detector scans across an entire microtiter plate, thus can read two fluorophores from any microtiter formatted sample array (96-well, 384-well, or other) within a few minutes. Background wells with no cells or tissue are included for background subtraction.
  • the PAS stain IR fluorescence is glycogen specific, as diastase digestion of cellular glycogen mediates a time-dependent decrease in signal of about 2-fold ( Figure 2 ).
  • PAS IR fluorescence detection at 700 nm and 800 nm was demonstrated to be a viable method for easily quantitating relative glycogen levels in cells.
  • fibroblasts derived from a severe patient with Pompe disease a glycogen storage disease
  • IR fluorescence was significantly greater than in normal fibroblasts.
  • the PAS signal was glycogen specific, as it was reduced after digestion with diastase.
  • This approach can be extended to quantify absolute amounts of glycogen in cells and tissues by combining PAS staining of varying concentrations of an external glycogen standard, and quantifying the IR fluorescence emitted from these standard concentrations.
  • a linear or non-linear regression analysis can be performed on the standard curve data, and the theoretical line or curve can be used to calculate absolute glycogen values from samples stained with PAS and measured using IR detection.
  • FIGS 3A and 3B depict fluorescent imaging of control CRL-2076 and PM-12 cells, respectively. While this method can detect glycogen in samples, it is very tedious to quantitate absolute levels of glycogen. Moreover, it is less amenable for high-throughput applications, since automated 96-well or higher density microtiter plate fluorescence readers and scanners are usually not viable alternatives for visible range measurements due to low depth and spatial resolution that cannot overcome high background due to autofluorescence of biological materials in the visible range. As the number of samples increase, and the number of fluorophores that are imaged per sample increase, data acquisition and processing time is proportionally increased, and throughput is proportionally decreased.
  • Pompe disease is a rare disease affecting only about one in 40,000 individuals, and as a result, is under- and misdiagnosed. Compounding this, severity, age at onset, rate of disease progression, and extent of organ involvement can vary significantly from individual to individual. Conclusive diagnosis generally requires an enzyme assay test to demonstrate reduced or absent activity for the lysosomal enzyme acid ⁇ -glucosidase (GAA), using cultured skin fibroblasts, muscle biopsies, and lymphocytes.
  • GAA ⁇ -glucosidase
  • glycogen accumulation in tissues of infantile-onset Pompe patients can be monitored pre- and post-treatment, which may be a measure of efficacy or may ultimately provide a correlation with clinical outcome.
  • IR fluorescence has superior signal-to-noise, and signal penetration from thick tissues. It is also readily quantifiable and compatible with high-throughput applications. IR fluorescence detection is superior to optical density measurement and visible light fluorescence measurement for glycogen content quantification from stained cells or tissues.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Developing Agents For Electrophotography (AREA)

Claims (15)

  1. Verfahren zum Nachweis von Polysacchariden in einer biologischen Probe, bei dem man die Probe einer PAS(Periodic Acid Schiff)-Färbung unterzieht und anschließend emittiertes Licht im Infrarotbereich nachweist.
  2. Verfahren nach Anspruch 1, wobei der Nachweis bei einer Wellenlänge im Bereich von etwa 700 nm bis 800 nm erfolgt.
  3. Verfahren nach Anspruch 1, wobei es sich bei dem Polysaccharid um Glykogen handelt.
  4. Verfahren nach Anspruch 1, wobei die biologische Probe aus einem menschlichen Patienten stammt, bei dem eine Glykogenspeicherkrankheit vermutet wird.
  5. Verfahren nach Anspruch 4, wobei die Glykogenspeicherkrankheit aus der aus Morbus Pompe, Morbus Cori-Forbes, Morbus Andersen, Morbus Tarui, Morbus McArdle, Phosphorylase-b-Kinase-Mangel (Glykogenose Typ VIII), Glykogen-Verzweigungsenzym-Mangel bei Pferden, Phosphoglyceratkinase-Isoform-A-Mangel (Glykogenose IX), Phosphoglycerat-M-Mutase-Mangel (Glykogenose Typ X), Triosephosphat-Isomerase-(TIM-)Mangel; pulmonale interstitielle Glykogenose; diabetische Nephropathie und Lafora-Krankheit (Myoklonus-Epilepsie) bestehenden Gruppe ausgewählt ist.
  6. Verfahren nach Anspruch 5, wobei es sich bei der Glykogenspeicherkrankheit um Morbus Pompe handelt.
  7. Verfahren nach Anspruch 6, wobei es sich bei der Glykogenspeicherkrankheit um infantilen Morbus Pompe handelt.
  8. Verfahren nach Anspruch 7, wobei es sich bei der biologischen Probe um isolierte Zellen oder isoliertes Gewebe, ausgewählt aus der aus Leber, Niere, Herz, Gehirn und Skelettmuskel bestehenden Gruppe, handelt.
  9. Verfahren nach Anspruch 1, bei dem man ferner den in der biologischen Probe vorliegenden Polysaccharidspiegel quantifiziert, indem man die emittierte Lichtmenge mit der von Standards bekannter Polysaccharidmengen emittierten Menge vergleicht.
  10. Verfahren zum Nachweis von Glykogen in einer biologischen Probe aus einem Patienten mit Morbus Pompe bzw. aus einem Patienten, bei dem Morbus Pompe vermutet wird, wobei man bei dem Verfahren die Probe einer PAS(Periodic Acid Schiff)-Färbung unterzieht und anschließend das emittierte Licht im Infrarotbereich nachweist.
  11. Verfahren nach Anspruch 10, wobei der Nachweis bei einer Wellenlänge im Bereich von etwa 700 nm bis 800 nm erfolgt.
  12. Verfahren nach Anspruch 10, wobei es sich bei der biologischen Probe um isolierte Zellen oder isoliertes Gewebe, ausgewählt aus der aus Leber, Niere, Herz, Gehirn und Skelettmuskel bestehenden Gruppe, handelt.
  13. Verfahren nach Anspruch 10, bei dem man ferner den in der biologischen Probe vorliegenden Polysaccharidspiegel quantifiziert, indem man die emittierte Lichtmenge mit der von Standards bekannten Glykogenmengen emittierten Menge vergleicht.
  14. Verfahren zur Überwachung der Wirksamkeit der Behandlung eines Patienten gegen eine Glykogenspeicherkrankheit, wobei man bei dem Verfahren
    i) Glykogen in einer dem Patienten vor Beginn der Behandlung entnommenen ersten biologischen Probe gemäß dem Verfahren nach Anspruch 1 nachweist,
    ii) Glykogen in einer dem Patienten nach Beginn der Behandlung entnommenen zweiten biologischen Probe gemäß dem Verfahren nach Anspruch 1 nachweist,
    iii) die Glykogenspiegel in den beiden Proben quantifiziert und
    iv) den Glykogenspiegel in der ersten Probe mit dem Glykogenspiegel in der zweiten Probe vergleicht,
    wobei eine Senkung des Glykogenspiegels in der zweiten Probe darauf hindeutet, dass die Behandlung wirksam ist.
  15. Verfahren nach Anspruch 14, wobei es sich bei der Glykogenspeicherkrankheit um Morbus Pompe handelt.
EP08745665A 2007-04-13 2008-04-11 Pas-färbung mit nachweis im infrarotbereich Not-in-force EP2145187B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91168807P 2007-04-13 2007-04-13
PCT/US2008/060104 WO2008128098A1 (en) 2007-04-13 2008-04-11 Periodic acid schiff staining with detection in the infrared range

Publications (3)

Publication Number Publication Date
EP2145187A1 EP2145187A1 (de) 2010-01-20
EP2145187A4 EP2145187A4 (de) 2010-10-27
EP2145187B1 true EP2145187B1 (de) 2012-03-07

Family

ID=39864343

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08745665A Not-in-force EP2145187B1 (de) 2007-04-13 2008-04-11 Pas-färbung mit nachweis im infrarotbereich

Country Status (6)

Country Link
US (1) US8283180B2 (de)
EP (1) EP2145187B1 (de)
AT (1) ATE548654T1 (de)
CA (1) CA2683840A1 (de)
ES (1) ES2383104T3 (de)
WO (1) WO2008128098A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013089817A1 (en) * 2011-12-16 2013-06-20 Li-Cor, Inc. Luminescence imaging scanner
CN112683632A (zh) * 2021-01-13 2021-04-20 贵州省农作物品种资源研究所 测定白及块茎中白及多糖含量的方法
CN119827264B (zh) * 2025-03-20 2025-06-03 南京金域医学检验所有限公司 一种提高肾穿刺特殊染色准确性的质控系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6410177A (en) * 1987-07-02 1989-01-13 Takara Shuzo Co Fluorescent labeling method for saccharides
JP3470055B2 (ja) * 1999-01-22 2003-11-25 株式会社渡邊商行 Ｍｏｃｖｄ用気化器及び原料溶液の気化方法
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
EP2932982B1 (de) * 2005-05-17 2018-10-03 Amicus Therapeutics, Inc. Verfahren zur Behandlung der Pompe-Krankheit mit 1-desoxynojirimycin und Derivaten

Also Published As

Publication number Publication date
ATE548654T1 (de) 2012-03-15
CA2683840A1 (en) 2008-10-23
US20100178667A1 (en) 2010-07-15
WO2008128098A1 (en) 2008-10-23
US8283180B2 (en) 2012-10-09
ES2383104T3 (es) 2012-06-18
EP2145187A4 (de) 2010-10-27
EP2145187A1 (de) 2010-01-20

Similar Documents

Publication Publication Date Title
Chen et al. Nanostructured biosensor for detecting glucose in tear by applying fluorescence resonance energy transfer quenching mechanism
Hu et al. Current trends in blood biomarker detection and imaging for Alzheimer’s disease
Lin et al. Membrane-activated fluorescent probe for high-fidelity imaging of mitochondrial membrane potential
US9340821B2 (en) Specific fluorescent probe based on albumin pseudo-esterase hydrolysis reaction and use thereof
Kumar et al. Porous silicon Fabry–Pérot interferometer for N-acetyl-β-d-glucosaminidase biomarker monitoring
Liu et al. Fluorescent neuraminidase assay based on supramolecular dye capture after enzymatic cleavage
Phan et al. Nanomaterial-based Optical and Electrochemical Biosensors for Amyloid beta and Tau: Potential for early diagnosis of Alzheimer’s Disease
Brown et al. Tale of two alkaloids: pH-controlled electrochemiluminescence for differentiation of structurally similar compounds
Nirala et al. N-acetyl-β-d-glucosaminidase activity assay for monitoring insulin-dependent diabetes using Ag-porous Si SERS platform
Chen et al. Application of SERS in In‐Vitro Biomedical Detection
CN105181973A (zh) 糖尿病肾病早期检测标记组合物，试剂盒及其使用方法
Ye et al. Dual-signal triple-mode optical sensing platform for assisting in the diagnosis of kidney disorders
EP2145187B1 (de) Pas-färbung mit nachweis im infrarotbereich
Han et al. Mitochondrial-targeted ratiometric near-infrared fluorescence probe for monitoring nitric oxide in rheumatoid arthritis
Dinish et al. Diffuse optical spectroscopy and imaging to detect and quantify adipose tissue browning
Zhang et al. Dual-State Emissive Mitochondrial Viscosity Probe for Long-Term Imaging of Rheumatoid Arthritis
EP2867673B1 (de) Kohlenhydratnachweis
Nirala et al. N-acetyl-β-D-glucosaminidase biomarker quantification in milk using Ag-porous Si SERS platform for mastitis severity evaluation
García et al. Plasmonic Detection of Carbohydrate‐Mediated Biological Events
Zhang et al. Distinguishing asphyxia from sudden cardiac death as the cause of death from the lung tissues of rats and humans using Fourier transform infrared spectroscopy
He et al. A quinolinium-based dual-functional NIR fluorescent probe for the imaging of Aβ aggregation and mitochondrial pH
Xia et al. Ultrasensitive Chemiluminescence Probes Designed from Covalent Inhibitors for SRAS-CoV-2 Mpro Detection
Morsby et al. Advances in Optical Sensors of N-Acetyl-β-d-hexosaminidase (N-Acetyl-β-d-glucosaminidase)
Li et al. A machine learning-driven SERS platform for precise detection and analysis of vascular calcification
Fasano et al. Assessment of the FRET-based Teen sensor to monitor ERK activation changes preceding morphological defects in a RASopathy zebrafish model and phenotypic rescue by MEK inhibitor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091019

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/52 20060101AFI20100916BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100928

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602008013963

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: G01N0033551000

Ipc: G01N0033520000

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/52 20060101AFI20110704BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 548654

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120315

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008013963

Country of ref document: DE

Effective date: 20120503

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2383104

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20120618

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120607

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120307

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120307

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20120307

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120307

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120307

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120608

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 548654

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120307

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120307

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120307

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120307

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120307

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120307

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120307

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120307

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120307

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120707

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120307

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120709

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120430

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120307

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120411

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120430

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120430

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120307

26N No opposition filed

Effective date: 20121210

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008013963

Country of ref document: DE

Effective date: 20121210

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120307

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120607

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120307

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120411

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20140311

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080411

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20140409

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20140422

Year of fee payment: 7

Ref country code: NL

Payment date: 20140410

Year of fee payment: 7

Ref country code: DE

Payment date: 20140430

Year of fee payment: 7

Ref country code: FR

Payment date: 20140409

Year of fee payment: 7

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602008013963

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20150411

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20150501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150411

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150411

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151103

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20151231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150501

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20160526

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150412